Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516374 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

Vaccine therapy of colorectal cancer patients with tumor antigens. Edition No. 1

VDM Publishing House, Nov 2010, Pages: 144


  Description  
   Authors   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

For the first time two tumor-associated antigens were evaluated as adjuvant therapy in combination with granulocyte colony stimulating factor (GM-CSF) for patients with colorectal cancer. The ?rst study involved immunization with the protein, carcinoembryonic antigen (CEA) during one year. This vaccination regimen induced a strong immunoglobulin 1 (IgG1) and IgG4 and a moderate IgG2 response against CEA. The humoral as well as the T cell responses were protracted up to 36 months. The dose of CEA had no or modest effect on these responses. The anti-CEA IgG titers related signi?cantly to survival. Functional HLA-DR epitopes of CEA could be de?ned which may serve as components of a vaccination strategy. The other vaccine strategy consisted of the epithelial cell adhesion molecule (Ep-Cam) expressed as a transgene in a viral vector, ALVAC. Patients were immunized over 6 weeks. No anti-Ep-Cam speci?c humoral response was induced, but eventually Ep-Cam speci?c type 1 T cells were induced. Both vaccines were well tolerated. GM-CSF augmented the responses. A low incidence of GM-CSF antibodies that did not neutralize the effect of GM-CSF was observed.



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds